Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA32067
Max Phase: Preclinical
Molecular Formula: C12H14N4O
Molecular Weight: 230.27
Molecule Type: Small molecule
Associated Items:
ID: ALA32067
Max Phase: Preclinical
Molecular Formula: C12H14N4O
Molecular Weight: 230.27
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Nc1ncc(Cc2cccc(CO)c2)c(N)n1
Standard InChI: InChI=1S/C12H14N4O/c13-11-10(6-15-12(14)16-11)5-8-2-1-3-9(4-8)7-17/h1-4,6,17H,5,7H2,(H4,13,14,15,16)
Standard InChI Key: LFEJRVMXZUZEDH-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 230.27 | Molecular Weight (Monoisotopic): 230.1168 | AlogP: 0.72 | #Rotatable Bonds: 3 |
Polar Surface Area: 98.05 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 7.16 | CX LogP: 0.99 | CX LogD: 0.80 |
Aromatic Rings: 2 | Heavy Atoms: 17 | QED Weighted: 0.72 | Np Likeness Score: 0.07 |
1. Doweyko AM.. (1988) The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules., 31 (7): [PMID:3290487] [10.1021/jm00402a025] |
2. Selassie CD, Fang ZX, Li RL, Hansch C, Debnath G, Klein TE, Langridge R, Kaufman BT.. (1989) On the structure selectivity problem in drug design. A comparative study of benzylpyrimidine inhibition of vertebrate and bacterial dihydrofolate reductase via molecular graphics and quantitative structure-activity relationships., 32 (8): [PMID:2502631] [10.1021/jm00128a035] |
3. Loukas YL.. (2001) Adaptive neuro-fuzzy inference system: an instant and architecture-free predictor for improved QSAR studies., 44 (17): [PMID:11495588] [10.1021/jm000226c] |
4. Crippen GM.. (1997) Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data., 40 (20): [PMID:9379435] [10.1021/jm970211n] |
5. So SS, Richards WG.. (1992) Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors., 35 (17): [PMID:1507206] [10.1021/jm00095a016] |
6. Ghose AK, Crippen GM.. (1985) Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors., 28 (3): [PMID:3882967] [10.1021/jm00381a013] |
7. Li RL, Poe M.. (1988) Quantitative structure-activity relationships for the inhibition of Escherichia coli dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines., 31 (2): [PMID:3276891] [10.1021/jm00397a017] |
8. Li R, Hansch C, Kaufman BT.. (1982) A comparison of the inhibitory action of 5-(substituted-benzyl)-2,4-diaminopyrimidines on dihydrofolate reductase from chicken liver with that from bovine liver., 25 (4): [PMID:7069722] [10.1021/jm00346a020] |
9. Selassie CD, Li R, Hansch C, Khwaja TA, Dias CB.. (1982) Inhibition by 5-(substituted-benzyl)-2,4-diaminopyrimidines of murine tumor (L5178Y) cell cultures sensitive to and resistant to methotrexate. Further evidence for the sensitivity of resistant cells to hydrophobic drugs., 25 (5): [PMID:7086836] [10.1021/jm00347a007] |
10. Selassie CD, Li RL, Poe M, Hansch C.. (1991) On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted-benzyl)pyrimidines with dihydrofolate reductase., 34 (1): [PMID:1899453] [10.1021/jm00105a008] |
11. Li RL, Dietrich SW, Hansch C.. (1981) Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted-benzyl)-2,4-diaminopyrimidines., 24 (5): [PMID:7017146] [10.1021/jm00137a012] |
12. Selassie CD, Fang ZX, Li RL, Hansch C, Klein T, Langridge R, Kaufman BT.. (1986) Inhibition of chicken liver dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines. A quantitative structure-activity relationship and graphics analysis., 29 (5): [PMID:3701780] [10.1021/jm00155a006] |
13. Hansch C, Li R, Blaney JM, Langridge R.. (1982) Comparison of the inhibition of Escherichia coli and Lactobacillus casei dihydrofolate reductase by 2,4-diamino-5-(substituted-benzyl)pyrimidines: quantitative structure-activity relationships, X-ray crystallography, and computer graphics in structure-activity analysis., 25 (7): [PMID:6809941] [10.1021/jm00349a003] |
Source(1):